Patients receiving systemic treatment with any immunosuppressive medication (other than steroids as described above). Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL- or anti-IL- receptor [IL-R]) Participants receiving systemic treatment with any immunosuppressive medication (other than steroids as described above) Patients receiving systemic treatment with any immunosuppressive medication, excepting the above Any condition requiring concurrent systemic immunosuppressive therapy Chronic immunosuppressive therapy Chronic immunosuppressive therapy On stable immunosuppressive regimen for weeks prior to enrollment; adjustment of immunosuppressive medications to maintain a therapeutic level is permitted Patients must have received some immunosuppressive chemotherapy in the preceding months. Ongoing immunosuppressive therapy. Treatment with systemic immunosuppressive medication within weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study Receiving immunosuppressive therapy including chronic steroids (except physiologic maintenance doses), methotrexate, or other known immunosuppressive agents Ongoing treatment with immunosuppressive drugs Regular immunosuppressive therapy TREATMENT WITH SJCAR: Receiving systemic immunosuppressive therapy in the days prior to CAR T-cell infusion Systemic therapy with immunosuppressive agents within days before enrollment Treatment with systemic immunosuppressive medication; Receiving immunosuppressive therapy Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until weeks after removal from immunosuppressive treatment A requirement for systemic immunosuppressive therapy for any reason Patients receiving concomitant immunosuppressive agents for medical condition Has a history of the following immunosuppressive conditions: bone marrow transplantation, and/or organ transplants and/or chronic rheumatic conditions that require active immunosuppressive therapy; patients with chronic lymphoid/leukemic malignancies that have undergone treatment in the last months will be ineligible Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy Immunosuppressive therapy within days prior to the first dose of trial treatment Patients must not be receiving active immunosuppressive therapy. Patients receiving systemic treatment with any immunosuppressive medication. Patients on immunosuppressive agents Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agents Patients on or requiring immunosuppressive therapies Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until weeks after removal from immunosuppressive treatment Administration of immunosuppressive drugs less than weeks prior to first dose of ERC Systemic immunosuppressive therapy in the past days Patients must not be receiving active immunosuppressive therapy. received immunosuppressive therapy < months prior to study Day Systemic cytotoxic or immunosuppressive therapy to be administered concomitantly while participating on this study; Need for ongoing treatment with an immunosuppressive agent Is currently treated with systemic immunosuppressive agents, including steroids, are ineligible until weeks after removal from immunosuppressive treatment Patients on chronic steroid use or other immunosuppressive agents Has a diagnosis of immunosuppressive disorder OR is on any other form of immunosuppressive therapy within days prior to transplant admission Any heart or lung transplant patient on immunosuppressive agents; renal transplant patients are allowed if patient is willing to reduce immunosuppressive agents and understand risk of rejection and possible need to return to dialysis; patients with chronic lymphocytic leukemia (CLL) or other hematologic malignancies are allowed Patients who require systemic corticosteroid or other immunosuppressive therapy; immunosuppressive therapy must be stopped at least days prior to cell infusion A requirement for systemic immunosuppressive therapy for any reason Patients needing chronic, immunosuppressive systemic steroids are excluded Patients needing chronic, immunosuppressive systemic steroids are excluded No change in systemic immunosuppressive therapy (type or intensity level) within weeks prior to enrollment Systemic immunosuppressive therapy for any reason Expected need for regular immunosuppressive therapy Active systemic immunosuppressive therapy Concurrent immunosuppressive therapy and no known immunosuppressive disease other than primary tumour Ongoing immunosuppressive therapy Use of immune modulators and/or any immunosuppressive drugs. Receiving immunosuppressive therapy Immunosuppressive therapy Use of systemic immunosuppressive drugs Patients receiving chronic treatment with systemic steroids or another immunosuppressive agent. Patients with known immunodeficiency or receiving immunosuppressive therapies Patients receiving systemic treatment with any immunosuppressive medication. Systemic immunosuppressive medication within weeks prior to study drug Patients on immunosuppressive therapy including: No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug Any condition requiring concurrent systemic immunosuppressive therapy Immunosuppressive disease A requirement for chronic systemic immunosuppressive therapy for any reason Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema Patients must have no evidence of active graft-versus-host disease and must be on a stable immunosuppressive regimen (or no immunosuppressive medications) without a change in drugs dosage in the weeks prior to the planned CD+ memory T cell infusion Immunosuppressive agents (unless required for treating potential AEs) Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema Chronic treatment with systemic steroids or another immunosuppressive agent Patients on immunosuppressive drugs (with exception of corticosteroid) Ongoing immunosuppressive therapy within days prior to the start of study therapy; use of immunosuppressive therapy, including systemic steroids within days before the first dose of SG. Receiving immunosuppressive drugs Patients requiring continuous, systemic immunosuppressive therapy Chronic treatment with systemic steroids or another immunosuppressive agent Need for ongoing treatment with an immunosuppressive agent. Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until weeks after removal from immunosuppressive treatment Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents; Use of any systemic immunosuppressive agents On immunosuppressive therapy. Receiving immunosuppressive therapy Subjects with conditions requiring chronic steroid or immunosuppressive treatment Chronic treatment with systemic steroids or another immunosuppressive agent Immunosuppressive therapy within the last months Patients on immunosuppressive drugs (with exception of corticosteroid) Subjects with immunosuppressive disease that require use of systemic steroids or immunosuppressive treatment immunodeficiency, immune compromised state or receiving immunosuppressive therapy No addition or subtraction of other immunosuppressive medications (e.g., calcineurin inhibitors, sirolimus, mycophenolate mofetil) for weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug Patients on chronic immunosuppressive medications, including steroids, within the past three months No addition or subtraction of other immunosuppressive medications (e.g., calcineurin inhibitors, sirolimus, mycophenolate mofetil) for weeks prior to enrollment; the dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other known immunosuppressive agents Need for chronic immunosuppressive drugs Need for chronic immunosuppressive drugs Patients who take immunosuppressive medication, i.e. steroid therapy or other immunosuppressive/immunomodulating drugs (e.g. Cyclosporine) within months prior to first study drug injection Is taking immunosuppressive therapy Chronic immunosuppressive therapy within days of screening Confirmed or suspected immunosuppressive or immunodeficient condition Treatment with systemic immunosuppressive medication Receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate Are immunosuppressed or in chronic use of immunosuppressive drugs. ongoing chronic immunosuppressive therapy The participant is receiving therapy with immunosuppressive agents. The participant is receiving therapy with immunosuppressive agents.